Table 1 Baseline clinical features

Age, year

54.95 ± 11.92

55.00 ± 11.58

Sex

 Male

163 (69.36%)

60 (71.43%)

 Female

72 (30.64%)

24 (28.57%)

TNM stage

 I

43 (18.30%)

6 (7.14%)

 II

66 (28.09%)

18 (21.43%)

 III

83 (35.32%)

37 (44.05%)

 IV

43 (18.30)

23 (27.38%)

Tumor stage

 T1

42 (17.87%)

6 (7.14%)

 T2

25 (10.64%)

5 (5.95%)

 T3

76 (32.34%)

29 (34.52%)

 T4

92 (39.15%)

44 (52.38%)

Node stage

 N0

62 (26.38%)

15 (17.86%)

 N1

41 (17.45%)

12 (14.29%)

 N2

43 (18.30%)

17 (20.24%)

 N3

89 (37.87%)

40 (47.62%)

Metastasis

 No

192 (81.70%)

61 (72.62%)

 Yes

43 (18.30%)

23 (27.38%)

Location

 1

33 (14.04%)

14 (16.67%)

 2

56 (23.83%)

23 (27.38%)

 3

109 (46.38%)

32 (38.10%)

 4

37 (15.74%)

15 (17.86%)

AST, U/L

 ≤ 22.8

17.51 ± 2.66

17.65 ± 3.70

 > 22.8

35.15 ± 21.05

44.82 ± 34.85

ALT, U/L

 ≤ 30.1

16.67 ± 5.37

17.89 ± 5.94

 > 30.1

56.41 ± 41.03

65.97 ± 47.55

LDH, U/L

 ≤ 168.7

142.59 ± 16.72

146.24 ± 17.25

 > 168.7

206.02 ± 54.78

289.90 ± 353.72

GGT, U/L

 ≤ 26.9

16.52 ± 5.09

17.39 ± 5.02

 > 26.9

51.02 ± 45.46

55.67 ± 57.97

TBA, μmol/L

 ≤ 5.4

2.86 ± 1.25

3.21 ± 1.22

 > 5.4

12.76 ± 10.41

13.10 ± 8.99

ALP, U/L

 ≤ 80

61.72 ± 11.77

60.94 ± 10.51

 > 80

98.59 ± 25.85

120.26 ± 83.86

ALB, g/L

 ≤ 38.8

34.86 ± 3.74

36.16 ± 1.97

 > 38.8

42.56 ± 2.42

43.03 ± 2.48

TBIL, μmol/L

 ≤ 7.3

5.78 ± 1.26

5.98 ± 0.94

 > 7.3

13.11 ± 4.77

12.40 ± 4.78

ApoA1, g/L

 ≤ 1.1

0.96 ± 0.13

0.96 ± 0.12

 > 1.1

1.34 ± 0.19

1.33 ± 0.21

ApoB, g/L

 ≤ 1.1

0.84 ± 0.16

0.82 ± 0.16

 > 1.1

1.44 ± 0.79

1.17 ± 0.04

PT, S

 ≤ 11.9

11.11 ± 0.47

11.09 ± 0.52

 > 11.9

12.56 ± 0.67

12.95 ± 1.66

Fbg, g/L

 ≤ 3.6

2.63 ± 0.56

2.68 ± 0.54

 > 3.6

4.35 ± 0.67

4.27 ± 0.70